BioCentury

8:00 AM GMT, Feb 7, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Status

Bapineuzumab: Completed Phase III enrollment

Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Pfizer Inc. (NYSE:PFE), New

Read the full 122 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.